Marina Chiara Garassino, MD

Articles

Dr. Garassino on Safety Protocols for Patients With Cancer in Italy During COVID-19

May 13th 2021

Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

Dr. Garassino on the Rationale for the PACIFIC-6 Trial in NSCLC

March 25th 2021

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

Dr. Garassino on COVID-19 Vaccine Distribution to Patients With Cancer in Italy

February 25th 2021

Marina Garassino, MD, discusses the distribution of the coronavirus disease 2019 vaccine to patients with cancer in Italy.

Dr. Garassino on Erlotinib/Ramucirumab Versus Osimertinib in EGFR+ NSCLC

June 13th 2019

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the combination of erlotinib (Tarceva) and ramucirumab (Cyramza) versus osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Garassino Discusses PROs With Durvalumab by PD-L1 Expression in Stage III NSCLC

April 25th 2019

Marina Chiara Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses patient reported outcomes with durvalumab by PD-L1 expression in patients with stage III unresectable non–small cell lung cancer.

Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

April 12th 2018

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

November 1st 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

October 31st 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

Dr. Garassino Discusses Recent Pivotal Immunotherapy Findings in NSCLC

October 19th 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

Dr. Garassino on the PACIFIC Trial for NSCLC

September 20th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).